PolyActiva has reported positive results from the Phase IIa trial of PA5108 Ocular Implant in primary open-angle glaucoma (POAG) patients.
The multicentre, open-label Phase IIa trial has assessed the PA5108 Ocular Implant’s minimum effective dose in mild to moderate POAG patients across three dose cohorts, with each cohort comprising ten subjects.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Mean diurnal intraocular pressure (IOP) at 12 and 26 weeks, as well as 8am IOP at 6, 18 and 21 weeks, when compared to the baseline were used as two of the study’s efficacy endpoints.
Developed using Prezia Sustained Drug Delivery Technology, the PA5108 Ocular Implant releases a constant daily dose of latanoprost free acid.
It also includes features such as zero-order drug release and quick, non-toxic biodegradation following the completion of treatment.
The Prezia Technology can also be used to deliver multiple drugs with one implant.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, it is said to be suitable for providing delivery from both the front and back of the eye.
The company stated that the PA5108 Ocular Implant met both the primary and secondary efficacy endpoints of at least 20% IOP reducing in the low-dose cohort.
PolyActiva CEO Russell Tait said: “We are excited to announce these positive Phase IIa results as they point to the significant benefit the PA5108 Ocular Implant with Prezia Technology may provide to the ophthalmic community and patients suffering from the effects of glaucoma.
“We look forward to further exploring its beneficial clinical impact as we move to the next phase of our clinical programme.”
